Search Result

Results for "

haemophilia A

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Factor VIII (3) Factor Xa (1) Ser/Thr Protease (1) Thrombin (1) Tissue Factor Pathway Inhibitor (TFPI) (2)
By Research Areas:	Cardiovascular Disease (3)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112998

Efmoroctocog alfa	Factor VIII	Cardiovascular Disease
Efmoroctocog alfa is a recombinant factor VIII-Fc fusion protein (rFVIIIFc). In mice with hemophilia A, Efmoroctocog alfa provides longer-lasting protection against tail vein transection injury than conventional rFVIII products. In dogs with hemophilia A, Efmoroctocog alfa produces a longer duration of improvement in whole blood clotting time than conventional rFVIII products. Efmoroctocog alfa can be used for research on hemophilia A .

HY-P99283

Concizumab 1 Publications Verification NN 7415; mAb 2021; Anti-TFPI Recombinant Antibody	Factor Xa	Others
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia .

HY-112865

Octocog alfa ADVATE; BAY 81-8973; Kovaltry	Factor VIII	Cardiovascular Disease
Octocog alfa (ADVATE; BAY 81-8973; Kovaltry) is a standard half-length recombinant coagulation factor FVIII replacement therapy that also functions as a thrombin generation modulator. Octocog alfa regulates thrombin generation-related parameters in vitro and is used in studies related to severe hemophilia A .

HY-114128

Turoctocog alfa pegol NN-7088; NN 7170	Factor VIII	Others
Turoctocog alfa pegol is a recombinant coagulation factor VIII (FVIII) from chinese hamster ovary (CHO) cells. Turoctocog alfa pegol can be used for researching haemophilia A .

HY-P99465

Befovacimab BAY 1093884	Thrombin Tissue Factor Pathway Inhibitor (TFPI)	Cardiovascular Disease
Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI). Befovacimab can be used for haemophilia A/B research .

HY-112935

Nonacog alfa BAX326; Coagulation Factor IX [Recombinant]; BeneFIX	Ser/Thr Protease	Others
Nonacog alfa (BAX326) is a recombinant human factor IX that can be used for the research of haemophilia B .

HY-P991379

MG1113A	Tissue Factor Pathway Inhibitor (TFPI)	Others
MG1113A is a human monoclonal antibody (mAb) targeting TFPI. MG1113A can be used in Haemophilia research.

Cat. No.	Product Name

HY-L171

Anti-Hematopathy Compound Library	4,232 compounds
Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs. MCE designs a unique collection of 4,232 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Anti-Hematopathy Compound Library

4,232 compounds

Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs.

MCE designs a unique collection of 4,232 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Cat. No.	Product Name	Target	Research Area	Image

HY-112998

Efmoroctocog alfa	Factor VIII	Cardiovascular Disease
Efmoroctocog alfa is a recombinant factor VIII-Fc fusion protein (rFVIIIFc). In mice with hemophilia A, Efmoroctocog alfa provides longer-lasting protection against tail vein transection injury than conventional rFVIII products. In dogs with hemophilia A, Efmoroctocog alfa produces a longer duration of improvement in whole blood clotting time than conventional rFVIII products. Efmoroctocog alfa can be used for research on hemophilia A .

HY-P99283

Concizumab 1 Publications Verification NN 7415; mAb 2021; Anti-TFPI Recombinant Antibody	Factor Xa	Others
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia .

HY-114128

Turoctocog alfa pegol NN-7088; NN 7170	Factor VIII	Others
Turoctocog alfa pegol is a recombinant coagulation factor VIII (FVIII) from chinese hamster ovary (CHO) cells. Turoctocog alfa pegol can be used for researching haemophilia A .

HY-P99465

Befovacimab BAY 1093884	Thrombin Tissue Factor Pathway Inhibitor (TFPI)	Cardiovascular Disease
Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI). Befovacimab can be used for haemophilia A/B research .

HY-P99840

Dalcinonacog alfa CB-2679d; DalcA; ISU-304	Inhibitory Antibodies	Others
Dalcinonacog alfa is a recombinant FIX factor that can be used in the study of Haemophilia B .

HY-112935

Nonacog alfa BAX326; Coagulation Factor IX [Recombinant]; BeneFIX	Ser/Thr Protease	Others
Nonacog alfa (BAX326) is a recombinant human factor IX that can be used for the research of haemophilia B .

HY-P991379

MG1113A	Tissue Factor Pathway Inhibitor (TFPI)	Others
MG1113A is a human monoclonal antibody (mAb) targeting TFPI. MG1113A can be used in Haemophilia research.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.